In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Valeant gets Elidel and Xerese rights in the US, Canada, and Mexico from Meda

Executive Summary

The same day specialty pharma Meda AB acquired global rights to Elidel (pimecrolimus) cream 1% from Novartis AG for $420mm, Meda made a commitment in principle to out-license US, Canadian, and Mexican rights to the drug to Valeant Pharmaceuticals International Inc. (skin and neurology drugs). Elidel has been approved for mild-to-moderate atopic dermatitis.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies